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Abstract
A framework is proposed for modelling the uncertainty in the measurement processes constituting the dosimetry chain that are
involved in internal absorbed dose calculations. The starting point is the basic model for absorbed dose in a site of interest as the
product of the cumulated activity and a dose factor. In turn, the cumulated activity is given by the area under a time–activity curve
derived from a time sequence of activity values. Each activity value is obtained in terms of a count rate, a calibration factor and a
recovery coefficient (a correction for partial volume effects). The method to determine the recovery coefficient and the dose
factor, both of which are dependent on the size of the volume of interest (VOI), are described. Consideration is given to
propagating estimates of the quantities concerned and their associated uncertainties through the dosimetry chain to obtain an
estimate of mean absorbed dose in the VOI and its associated uncertainty. This approach is demonstrated in a clinical example.
Keywords Dosimetry . Uncertainty analysis
Introduction
Internal dosimetry following the administration of radio
labelled pharmaceuticals for diagnostic and therapeutic
purposes is a prerequisite for radiation protection, imag-
ing optimization, patient-specific administrations and
treatment planning. The medical internal radiation dose
(MIRD) schema [1] has become the most widely accepted
formalism for internal dose calculations. The general ap-
proach in medicine to determine the validity of a measure-
ment is to compare the accuracy and precision against a
“gold standard” measurement. To date, investigations of
uncertainties for internal dosimetry have mainly used
phantoms or simulated data [2–4] as the gold standard
comparison. However, due to the diversity of dosimetry
data, a subset of phantom experiments cannot necessarily
validate the accuracy of measurements made for an in
vitro population. It is therefore more appropriate to ex-
press the accuracy of a result by characterizing the uncer-
tainty. This involves identification of the major processes
and variables within the dose calculation and evaluation
of their potential effect on the measurement. An uncer-
tainty estimate should address all systematic and random
sources of error and characterize the range of values with-
in which the measured value can be said to lie with a
specified level of confidence. The general relevance of
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performing and providing uncertainty information has
been discussed in previous guidelines [5]. Flux et al. [6]
provided a method to determine the uncertainty of whole-
body absorbed doses calculated from external probe mea-
surement data. Whilst whole-body dosimetry is used to
predict toxicity in some procedures [7, 8], organ and tu-
mour dosimetry are required for treatment planning and in
cases where haematotoxicity is not the limiting factor for
treatment tolerance.
Specific aspects of uncertainty within the dosimetry chain
have been addressed, including the selection of measured time
points, [9, 10], the chosen fit function [11, 12] and uncertainty
of model parameters. A comprehensive analysis of propaga-
tion of every aspect of the dosimetry calculation chain has yet
to be obtained.
Gustafsson et al. [13] adopted a Monte Carlo (MC) ap-
proach to investigate the propagation of uncertainties to
obtain an uncertainty in estimated kidney absorbed dose
in 177Lu-DOTATATE therapy, using simulated gamma-
camera images of anthropomorphic computer phantoms.
In principle, this approach allows all aspects of the dosim-
etry process to be taken into account, but the need for
multiple samplings from the assigned probability distribu-
tions for the quantities involved makes it computationally
intensive, and its use for uncertainty assessment in an in-
dividual patient basis is challenging.
The Joint Committee for Guides in Metrology (JCGM)
Guide to the Expression of Uncertainty in Measurement
(GUM) [14] provides a generalized schema for propagat-
ing uncertainties. This EANM Dosimetry Committee
guidance document provides recommendations on how
to determine uncertainties for dosimetry calculations and
apply the law of propagation of uncertainty (LPU) given
in the GUM to the MIRD schema. This guidance docu-
ment is presented in the form of an uncertainty propaga-
tion schema, and the recommendations are designed to be
implemented with the resources available in all nuclear
medicine departments offering radionuclide therapy, and
are presented using terminology and nomenclature that
adhere as far as possible to the GUM.
The uncertainty propagation schema examines each step
of the absorbed dose calculation to estimate the standard
uncertainty in the mean absorbed dose measured at the
organ or tumour level using SPECT imaging. The exam-
ples given have been simplified and concentrate only on
the mean absorbed dose to a target. However, the approach
can be used in different scenarios and expanded to include
more complex dose calculations, including cross-dose and
multiexponential time–activity curves (TACs). Similarly,
aspects of the methodologies described can be implement-
ed in different applications of dosimetry such as those uti-
lizing a hybrid imaging approach or those used to generate
3D dose maps.
Theory
The law of propagation of uncertainty
A generic multivariate measurement model is:
Y ¼ f Xð Þ; ð1Þ
where
X¼ X 1;…;X n½ ⊤ ð2Þ
is a vector of n generic input quantities X1,…, Xn and
Y¼ Y 1;…; Ym½ ⊤ ð3Þ
is a vector measurand ofm output quantities Y1,…, Ym. GUM
Supplement 2 [15] gives a generalization of the LPU:
Vy ¼ GxVxG⊤x ð4Þ
whereVy is the output covariancematrix associated with y (the
estimate of Y). Vx is the input covariance matrix
Vx ¼
u2 x1ð Þ … u x1; xnð Þ
⋮ ⋱ ⋮
u xn; x1ð Þ … u2 xnð Þ
24 35 ð5Þ
associated with
x ¼ x1;…; xn½ ⊤; ð6Þ
the estimate of X, and Gx is the sensitivity matrix associated
with x, defined as:
Gx¼
∂ f 1
∂x1
…
∂ f 1
∂xn
⋮ ⋱ ⋮
∂ f m
∂xn
…
∂ f m
∂xn
26664
37775; ð7Þ
where ∂fi/∂xj denotes ∂fi/∂Xj evaluated at X = x. Element
u(xi, xj) of Vx is the covarience associated with xi and xj, and
u(xi, xi) is equal to u
2(xi), the squared uncertainty associated
with xi. x and Vx are obtained from available knowledge,
whether statistical (for example, repeated observations) or
nonstatistical (for example, expert judgment), about the input
quantities.
For a generic scalar measurement model, Eq. 1 be-
comes Y = f(X), where Y is a scalar quantity and f is a
scalar function. Propagation of uncertainty for the esti-
mate y of Y can be achieved using the matrix form of the
LPU [15]:
u2 yð Þ ¼ g⊤xVxgx; ð8Þ
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where u2(y) represents the variance (squared standard
uncertainty) associated with the estimate y, and
gx ¼
∂ f
∂x1
⋮
∂ f
∂xn
26664
37775 ð9Þ
is the gradient matrix in which the ith element denotes
the partial derivative of f with respect to the quantity Xi
evaluated at x.
For a two-variable function, Y = f(X1, X2), Eq. 8 can be
expanded to give:
u2 yð Þ ¼ ∂ f
∂x1
 2
u2 x1ð Þ þ ∂ f∂x2
 2
u2 x2ð Þ
þ 2 ∂ f
∂x1
∂ f
∂x2
u x1; x2ð Þ: ð10Þ
For a two-variable multiplicative function, Y = X1X2,
Eq. 10 can be written in the form:
u yð Þ
y
 2
¼ u x1ð Þ
x1
 2
þ u x2ð Þ
x2
 2
þ 2 u x1; x2ð Þ
x1x2
: ð11Þ
If the two variables X1 and X2 are mutually independent,
the covariance term of Eq. 11 is zero, and therefore the stan-
dard fractional uncertainties u(x1)/x1 and u(x2)/x2 are simply
added in quadrature.
Absorbed dose
For situations where the target volume is the source activ-
ity volume and the contribution of absorbed dose from
other target organs can be considered negligible, a simpli-
fied form of the MIRD equation can be used in which mean
absorbed dose D is expressed as the product of the cumu-
lated activity ~A and the S-factor (sometimes called the dose
factor) S:
D ¼ ~AS: ð12Þ
Following the above notation, D is written as
D ¼ f ~A; S  ¼ ~AS, and the standard uncertainty u D  is
evaluated at estimates of ~A and S according to Eq. 11:
u D
 	
D
24 352 ¼ u ~A
 	
~A
24 352 þ u Sð Þ
S
 2
þ 2
u ~A; S
 	
~AS
: ð13Þ
It follows that the standard uncertainties u ~A
 
and u(S) and
the covariance u ~A; S
 
are needed to obtain the standard un-
certainty u D
 
associated with D.
For the general form of the MIRD equation with meaning-
ful contributions outside the target volume (cross-dose), un-
certainties and covariances associated with additional quanti-
ties of the form ~A and S should also be considered.
The need for the covariance term of Eq. 13 may not be
obvious on first inspection as calculations of ~A and S are
often considered separately, that is, one is derived from
scintigraphy data and the other from simulations.
However, as can be seen from Fig. 1 (a flow diagram of a
typical dosimetry protocol), determination of ~A and S both
rely on a measurement of volume, and therefore a covari-
ance exists between the two parameters. This EANM
Dosimetry Committee guidance document describes how
the uncertainty in the volume measurement and other con-
founding factors within the dosimetry protocol can be
propagated to estimate an overall uncertainty in absorbed
dose.
Volume uncertainty
The volume or mass of an organ or tumour is generally ob-
tained from a volume of interest (VOI) outlined on anatomical
or functional imaging data. It is therefore possible to estimate
the outlining accuracy by considering factors that affect delin-
eation. The method used will depend largely on the informa-
tion and resources available at the time of outlining and the
method employed by the operator or operators to define the
VOI. The following concerns an outline drawn manually by a
single operator across all images that comprise the dosimetry
dataset.
Operator variability
For any given dosimetry dataset a number of independent
VOIs could be drawn by different operators. Ideally, an
average VOI boundary of volume v would then be gener-
ated and used in the calculation of absorbed dose. In
practice, an average VOI boundary cannot be generated
and an absorbed dose calculation is based upon the VOI
drawn by a single operator. An alternative approach is
therefore to estimate operator variability using historical
datasets. In this case outlines previously generated by M
different operators for N similar VOIs are used. The as-
sumption made is that the VOIs are sufficiently similar
with respect to the scanning modality and volume geom-
etry that the fractional uncertainty is the same across all
datasets. The VOI outlined by the current operator is then
regarded as a random VOI drawn from the populations of
outlines represented by the historical data. The standard
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uncertainty u(v) associated with the drawn volume is then
expressed as:
u vð Þ
v
 2
¼ 1
N2
∑
N
n¼1
s vhistið Þ
vhisti
 2
; ð14Þ
where vhisti is the average of M operator volumes for the
historical dataset i, and s vhistið Þ is the standard deviation
of the historical dataset I,
s2 vhistið Þ ¼
∑Mm¼1 vm−vhistið Þ2
M−1
: ð15Þ
The historical datasets should be carefully chosen to match
the current study, as differences could lead to an inaccurate
estimate of the final standard deviation.
Analytical approach
When historical outlines are not available, it is possible to
use an analytical method to determine uncertainty. This
approach provides an estimate of the most significant con-
tributions to the uncertainty in the outlining process but is
not necessarily exhaustive.
Given that any outlined VOI will be digitized into voxels,
the extent of the VOI will be defined, approximately, by the
subset of voxels through which the boundary of the VOI
passes. The uncertainty of the outlined volume will hence
depend on voxel size. Figure 2 shows an outline (Fig. 2a)
and the effect of different voxel sizes (Fig. 2b, c).
The mass of a spherical volume may be obtained from an
estimate of the diameter of the volume, where the diameter d is
measured as the distance between two extreme points, PI and
Pj, the locations of which can be determined within one voxel
dimension (Fig. 3).
Evaluation of the standard uncertainty associated with d
can be considered as type B (nonstatistical), as in the GUM
Acquire patient
dosimetry scans
Fit function to 
recovery data
Draw VOI and 
determine volume 
Use VOI volume to
determine recovery factor
Measure counts in VOI
Calculate total activity
Within VOI
Fit function to TAC
Integrate TAC to determine
cumulated activity
Use VOI volume to
determined S-factor
Calculate absorbed dose
Fit function to S-factor dataAcquire calibration data
Acquire S-factor dataAcquire recovery curve data
Fig. 1 Flow diagram showing
chronological sequence of the
dosimetry schema demonstrating
how uncertainty can propagate
between each step
(a) (b) (c)
Fig. 2 Uncertainty in outline definition for different voxel sizes
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[14]. Given that there is no specific knowledge about the lo-
cation of point Pi on the boundary, other than that it lies within
the appropriate boundary voxel, there is a uniform distribution
of possible values with variance associated with the mean
value given by formula 7 in [14]:
u2 Pið Þ ¼ a
2
12
ð16Þ
where a is one voxel width and u(Pi) is to be interpreted as the
standard uncertainty associated with Piwhen measured on the
diametric line between Pi and the centre of the sphere. As
diametric measurement is the distance between two extreme
points, application of the variant of LPU [14] (formula 11a in
the GUM) yields (assuming no correlation) the standard un-
certainty uvox(d) associated with diameter d due to
voxelization:
u2vox dð Þ ¼ u2 Pi−P j
  ¼ a2
6
: ð17Þ
With hybrid imaging it is often possible to use morpholog-
ical information from CT imaging to aid functional VOI de-
lineation. In this situation the VOI is drawn on the CT dataset
and copied to the registered SPECT image. The coordinates of
the original boundary will therefore be rounded to the nearest
voxel coordinates of the SPECT image. Hence, the SPECT
voxel size should be used in Eq. 17.
For many scintigraphic imaging processes the defined vox-
el size is less than the spatial resolution of the system and
therefore the use of Eq. 17 would result in underestimation
of the actual uncertainty when the VOI is drawn directly on
the SPECT image. To provide a more reliable uncertainty the
spatial resolution of the image system must also be consid-
ered. Consider a profile through an object approximated as a
step function convolved with a Gaussian point spread function
(PSF) with the full-width at half-maximum (FWHM) equal to
the spatial resolution of the imaging system. The uncertainty
in edge definition can be described by the gradient of the
convolved step function, where the gradient profile is equal
to the Gaussian PSF with standard deviation σ ¼ FWHM
2
ﬃﬃﬃﬃﬃﬃ
2ln2
p . As
the diametric measurement is the distance between the bound-
ary locations on the profile, application of the variant of LPU
[14] (GUM formula 11a) yields the standard uncertainty
ures(d) associated with diameter d due to spatial resolution:
u2res dð Þ ¼ 2σ2 ¼
FWHM
2
ﬃﬃﬃﬃﬃﬃ
ln2
p Þ
2
:

ð18Þ
For situations where both voxelization and resolution con-
tribute significantly to diametric uncertainty (such as outlining
directly on a SPECT image), Eqs. 17 and 18 are summed to
give the combined uncertainty associated with d:
u2 dð Þ ¼ u2vox dð Þ þ u2res dð Þ ¼
a2
6
þ FWHMð Þ
2
4ln2
: ð19Þ
In practice the diameter is not measured and only the vol-
ume is reported. However, conceptually the volume is deter-
mined through an infinite number of diametric measurements,
and themean diameter of the VOI can therefore be considered.
The standard uncertainty u(d) translates into a standard uncer-
tainty u(v) associated with the volume v delineated by the
outline. Hence, for some positive constant k,
v ¼ kd3: ð20Þ
The application of the variant of LPU [14] (GUM formula
12) yields a relationship between the relative volume and di-
ametric uncertainties due to voxelization and resolution:
u vð Þ
v
 2
¼ 3 u dð Þ
d
 2
¼ 3 uvox dð Þ
d
 2
þ 3 ures dð Þ
d
 2
: ð21Þ
Hence, a fractional standard uncertainty associated with a
volume is three times the fractional standard uncertainty asso-
ciated with the mean diameter of that volume.
Count rate
The total reconstructed count rate, C, within a VOI de-
pends on the VOI delineation, and can be described as a
function of volume. Propagation of volume uncertainty
into the measurement of count rate is therefore required.
As no prior knowledge of the count distribution is gener-
ally available, the variation in C within the VOI must be
approximated.
A uniformly distributed spherical count rate density H(ρ)
with volume vtrue of radius r, with a total emission count rate
of Ctotal, can be described in spherical coordinates as:
H ρð Þ ¼
Ctotal
vtrue
; ρ < r;
0; ρ≥r;
(
ð22Þ
distance
Profile (step function)
Convolved Profile
Gradient Profile
S
ig
n
al
 in
te
n
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ty
Fig. 3 Signal intensity profiles demonstrating that the gradient of a
Gaussian blurred function can be described by the Gaussian function
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where ρ is the radial distance from the centre of the sphere.
Due to the spatial limitations of the measuring system the
apparent density is described as the spherical volume con-
volved with a 3D Gaussian function [16]:
G ρð Þ ¼ 1
σ
ﬃﬃﬃﬃﬃ
2π
p 3 e− ρ22σ2 ; ð23Þ
where σ is the measured standard deviation describing the
width of the 3D Gaussian function. Therefore, an observed
count rate density distribution can be described as:
F ρð Þ ¼ H ρð Þ*G ρð Þ; ð24Þ
where ∗ denotes convolution in three dimensions, which can
be determined analytically [17] and re-expressed as:
F ρð Þ ¼ Ctotal
2vtrue
erf
r−ρ
σ
ﬃﬃﬃ
2
p
 
þ erf r þ ρ
σ
ﬃﬃﬃ
2
p
 
−
2σ
ρ
ﬃﬃﬃﬃﬃ
2π
p e− r
2þρ2
2σ2
 
e
rρ
σ2
 
−e−
rρ
σ2
   
ð25Þ
The function F(ρ) and that of perfect resolution H(ρ) are
shown in Fig. 4a; images of these distributions are shown in
Fig. 4b.
Using Eq. 25, the count rate C measured within a VOI of
volume v and radius ρ can be expressed as:
C ¼ ∫v0F ρð Þdv; ð26Þ
as shown in Fig. 5, where C is described as the area under the
curve. A plot of this function with increasing ρ and v is given
in Fig. 5a.
As there is an uncertainty associated with the drawn VOI
boundary, the standard uncertainty u(C) associated with C is
obtained using the gradient of C at v (Fig. 5d) and the volume
standard uncertainty u(v):
u Cð Þ ¼ ∂C
∂v
u vð Þ ¼ F ρð Þu vð Þ: ð27Þ
For a VOI of volume v, where the radius ρ = r, the expres-
sion for F(ρ) as given by Eq. 25 can be substituted into Eq. 27:
∂C
∂v
u vð Þ ¼ Ctotalφ
2v
u vð Þ; ð28Þ
where
φ ¼ erf 2r
σ
ﬃﬃﬃ
2
p
 
−
2σ
r
ﬃﬃﬃﬃﬃ
2π
p 1−e− 2r
2
σ2
  
: ð29Þ
The ratio of the total emission count rate from a source
to the count rate measured within a VOI defining the phys-
ical boundary is referred to as the recovery coefficient [18]
(see section Recovery coefficient):
R ¼ C
Ctotal
: ð30Þ
Therefore, the standard uncertainty u(C) associated with C
can be rewritten as:
u Cð Þ
C
¼ φ
2R
u vð Þ
v
: ð31Þ
Recovery coefficient
There are a number of methods to correct for the observed
“spill out” of counts from an object due to partial volume
effects [16]. The simplest and most widely applied method
is to divide the observed count rate by a recovery coefficient
determined from phantom data. Dewaraja et al. [19] recom-
mend imaging multiple phantoms of various sizes and geom-
etries using the same acquisition and processing parameters as
used for the patient data. An appropriate recovery coefficient
is then selected based on the estimated object volume. The
recovery coefficient determined from a phantom of volume
vtrue is defined as:
R ¼ C
Ctotal
; ð32Þ
where C is the observed count rate measured within a VOI
matching the true volume of the phantom and Ctotal is the
count rate of all counts originating from the phantom [18].
(a) (b)
Fig. 4 a Count density as function of radius for a spherical object with
true radius r for a system with ideal resolution (red step function) and
realistic system (green curve). b Two-dimensional image planes through
the three-dimensional functions H(ρ) and F(ρ) (see text)
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A dataset comprising a series of volumes and the corre-
sponding factors on the right side of Eq. 32 is fitted by an
empirical function of appropriate form. Such a function will
have adjustable parameters b = [b1,…, bq]
T and will provide a
means for estimating a recovery factor specific to the volume
under investigation. The standard uncertainty u(R) associated
with the recovery factor can be derived from the fitted param-
eters b. A covariance matrix Vb of dimensions q × q corre-
sponds to the estimate of b determined by ordinary least
squares fitting under the assumption of equal uncertainty in
all data points that make up the dataset. For a perfectly spec-
ified volume v, the squared standard uncertainty associated
with R is, using Eq. 8:
u2 Rð Þ ¼ g⊤bVbgb; ð33Þ
where gb is the matrix of dimension q × 1 containing the par-
tial derivatives of first order of R with respect to b. The co-
variance matrix Vb can be determined as a by-product of the
least squares fitting process. In reality the standard uncertainty
u(R) obtained in this manner for a given volume will under-
estimate the actual uncertainty. To provide a more realistic
value for u(R), the standard uncertainty u(v) associated with
the clinical outlined volume v has to be taken into consider-
ation. Since this volume is independent of the recovery curve
parameters, there will be no covariance associated with v and
any of the bj. Accordingly, Vb in Eq. 33 is replaced by:
V b;v½  ¼ Vb 00⊤ u2 vð Þ
 
; ð34Þ
where 0 is a matrix of zeros of dimension q × 1 and gb is
extended by one element, namely the partial derivative of first
order of R(v) with respect to v.
Calibration factor
The final conversion of a partial volume-corrected count rate
to activity is achieved by the use of a quantification or cali-
bration factor. The sensitivity of the system is determined by
measuring the total count rate Cref of a source of known ac-
tivity Acal, commonly referred to as a “standard”, under the
same acquisition and reconstruction conditions as the study
data:
Q ¼ Cref
Acal
: ð35Þ
The quantification factor will therefore depend on the
standard activity measurement within the dose calibrator
and the reconstructed count rate, and its associated un-
certainty accordingly calculated. Methods to determine
dose calibrator uncertainty are described by Gadd et al.
[20]. Uncertainty in the measurement of reconstructed
counts within the standard should be determined statisti-
cally from a series of nominally identical observations.
The uncertainty of a single measurement can be obtained
by calculating the mean and standard deviation of that
series. The standard uncertainty u(Q) associated with Q
can be determined by Eq. 11, a variant of LPU [14], that
combines the fractional uncertainties of the dose
(a) (b)
(c) (d)
.
.
Fig. 5 a Count density as
function of radius showing
observed counts within a VOI of
radius ρ (green shaded area). b
Two-dimensional image plane
with the VOI outlined with radius
ρ (red line). c Count rate as a
function of VOI volume v
corresponding to a particular
choice of radius ρ. d Gradient of
the count rate with respect to the
VOI volume v
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calibrator measurement and repeated count measurements
in quadrature:
u Qð Þ
Q
 2
¼ u Acalð Þ
Acal
 2
þ u Crefð Þ
Cref
 2
: ð36Þ
Activity
The expression relevant to the assessment of the uncertainty
associated with the activity Ai determined from the measured
count rate Ci in a target VOI at time ti is:
Ai ¼ CiQR; ð37Þ
Equation 37 corresponds to all measurement times ti, for
i = 1,…, n. Using matrix notation:
A ¼
A1
⋮
An
24 35 ¼ 1
QR
C1
⋮
Cn
24 35: ð38Þ
Equation 38 is a multivariate measurement model
(section The law of propagation of uncertainty) with n +
2 input quantities Q, R, C1, …, Cn and n output quantities
A = [A1,…, An]
⊤. With no loss of generality, in order to
keep the mathematical expressions simpler than they oth-
erwise would be, only two of these activity values, name-
ly, Ai and Aj, are considered, measured at times ti and tj,
respectively:
A ¼ Ai
Aj
 
¼ 1
QR
Ci
C j
 
: ð39Þ
Equation 39 is a bivariate measurement model with four
input quantities Q, R, Ci and Cj, and two output quantities Ai
and Aj. Using Eq. 7,
G Q;R;Ci;C j½  ¼
−
Ai
Q
−
Ai
R
Ai
Ci
0
−
Aj
Q
−
Aj
R
0
Aj
C j
2664
3775; ð40Þ
and the input covariance matrix is:
V Q;R;Ci;C j½  ¼
u2 Qð Þ u Q;Rð Þ u Q;Cið Þ u Q;C j
 
u Q;Rð Þ u2 Rð Þ u R;Cið Þ u R;C j
 
u Q;Cið Þ u R;Cið Þ u2 Cið Þ u Ci;C j
 
u Q;C j
 
u R;C j
 
u Ci;C j
 
u2 C j
 
26664
37775: ð41Þ
Since Q is independent of volume and hence independent
of R, Ci and Cj, the covariance terms u(Q, R), u(Q,Ci) and
u(Q,Cj) are zero. Application of Eq. 7 then gives:
VA¼G Q;R;Ci;C j½ V Q;R;Ci;C j½ G⊤Q;R;Ci;C j½ 
¼ u
2 Aið Þ u Ai;Aj
 
u Ai;Aj
 
u2 Aj
   ð42Þ
as the covariance matrix for Ai and Aj, the elements of which
may be expressed as:
u Aið Þ
Ai
 2
¼ u Qð Þ
Q
 2
þ u Rð Þ
R
 2
þ u Cið Þ
Ci
 2
−2
u R;Cið Þ
RCi
; ð43Þ
u Ai;Aj
 
AiAj
¼ u Qð Þ
Q
 2
þ u Rð Þ
R
 2
þ u Ci;C j
 
CiC j
−
u R;Cið Þ
RCi
−
u R;C j
 
RC j
I≠ jð Þ:
ð44Þ
It follows that the covariances u(R,Ci) and u(Ci,Cj) asso-
ciated with Q, R and the Ci must be derived.
Regarding u(Ci, Cj) for this situation, Eq. 4 or, more
directly, by the use of formula F.2 in the GUM [14],
yields:
u Ci;C j
  ¼ ∂Ci
∂v
∂C j
∂v
u2 vð Þ: ð45Þ
Using Eqs. 28 and 30 gives:
u Ci;C j
  ¼ φCi
2Rv
φC j
2Rv
u2 vð Þ: ð46Þ
Hence:
u Ci;C j
 
CiC j
¼ φ
2Rv
h i2
u2 vð Þ ¼ u Cið Þ
Ci
 2
: ð47Þ
As both the recovery coefficient R and the measured count
rate Ci depend on the VOI outline they can be expressed as
functions of volume v. Again applying the GUM [14] (formu-
la F.2) and using Eqs. 28 and 30 gives:
u R;Cið Þ ¼ φCi2Rv
∂R
∂v
u2 vð Þ; ð48Þ
which, after rearrangement, can be expressed as:
u R;Cið Þ
RCi
¼ u R;C j
 
RC j
¼ φ
2R2v
∂R
∂v
u2 vð Þ: ð49Þ
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After substituting the covariance expressions of Eqs. 47
and 49 into Eqs. 43 and 44 it can be seen that:
u Aið Þ
Ai
 2
¼ u Ai;Aj
 
AiAj
¼ u Qð Þ
Q
 2
þ u Rð Þ
R
 2
þ u Cið Þ
Ci
 2
−
φ
R2v
∂R
∂v
u2 vð Þ ð50Þ
Given the equal fractional uncertainties for all the Ai and
with perfect covariance between the Ai and Aj, it is appropriate
to treat these uncertainties in a manner similar to a systematic
error. Hence the fractional uncertainties in activity can be
propagated into a systematic component of uncertainty for
cumulated activity us ~A
 
, where
u Aið Þ
Ai
 2
¼
us ~A
 	
~A
24 352: ð51Þ
Time–activity curve parameters
In addition to the systematic uncertainties associated with
quantification and volume determination, uncertainties in
the TAC data can arise from other sources such as image
noise, patient motion, registration and other imperfect
post-acquisition operations such as image reconstruction,
including scatter and attenuation corrections. Due to the
complexity of these operations, it is assumed that the un-
certainties associated with the compensation for effects
such as attenuation and scatter are negligible in compari-
son with the uncertainty associated with the compensation
for partial volume effects [13]. It is therefore more appro-
priate to measure the causality of imperfects in these cor-
rections, and to derive uncertainties in the fit parameters of
the TAC.
Estimates of the TAC parameters p = [p1,…, pq]
⊤ can be
determined by fitting data points (ti, Ai), i = 1, …, n, where
the ti denote the image acquisition times and Ai the corre-
sponding measured activities. A least squares approach is rec-
ommended, using nonlinear regression techniques to mini-
mize the objective function
χ2 ¼ ∑ Ai− f tið Þ½ 2 ð52Þ
with respect to p. Note that a weighting term to account for
the activity uncertainty is not included due to the covariant
nature of the uncertainty. Uncertainties of the fit parameters
are then estimated using:
Vp ¼ χ
2
n−q
J⊤p Jp
h i−1
ð53Þ
where Jp is the matrix of first-order partial derivatives of the
TAC model with respect to p, evaluated at A. The TAC is
generally represented as a sum of exponential functions. For
the purpose of presentation, only the case of a single exponen-
tial function is described:
f tð Þ ¼ A tð Þ ¼ A0e−λt; ð54Þ
where A0 is the activity at time zero and λ is the effective
decay constant, for which
Jp ¼
∂A1
∂A0
∂A1
∂λ
⋮ ⋮
∂An
∂A0
∂An
∂λ
26664
37775 ¼ e
−λt1 −A0t1e−λt1
⋮ ⋮
e−λtn −A0tne−λtn
24 35 ð55Þ
and
Vp ¼ u
2 A0ð Þ u A0;λð Þ
u A0;λð Þ u2 λð Þ
 
: ð56Þ
Cumulated activity
The cumulated activity is defined as the integral of the
TAC from time t = 0 to ∞, which for a single exponential
function is described simply by the ratio of the TAC pa-
rameters, that is:
~A ¼ ∫∞0 A tð Þdt ¼ ∫
∞
0 A0e
−λt dt ¼ A0
λ
: ð57Þ
Application of Eqs. 8 and 9 to Eq. 57 is used to
derive the component of uncertainty associated with ran-
dom effects:
u2r ~A
 	
¼ g⊤pVpgp ð58Þ
where
g⊤p ¼
∂~A
∂A0
;
∂~A
∂λ
" #
¼ 1
λ
; −
A0
λ2
 
; ð59Þ
and Vp is the covariance matrix for the estimates of the
TAC parameters p = [A0, λ]
⊤given in Eq. 53. After ex-
pansion of these matrices the component of uncertainty
associated with random effects in ~A can be expressed
as:
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ur ~A
 	
~A
24 352 ¼ u A0ð Þ
A0
 2
þ u λð Þ
λ
 2
−2
u A0;λð Þ
A0λ
: ð60Þ
Random and systematic components can be combined by
considering the general model:
x ¼ xnom þ r þ s; ð61Þ
where xnom is the nominal value of some parameter x, and r
and s are random and systematic effects, respectively. Then,
applying LPU:
u2 xð Þ ¼ u2 rð Þ þ u2 sð Þ: ð62Þ
For cumulated activity
u2 ~A
 	
¼ u2r ~A
 	
þ u2s ~A
 	
; ð63Þ
hence, using Eqs. 50, 51 and 60:
u ~A
 	
~A
24 352 ¼ u A0ð Þ
A0
 2
þ u λð Þ
λ
 2
−2
u A0;λð Þ
A0λ
þ u Qð Þ
Q
 2
þ u Rð Þ
R
 2
þ u CIð Þ
CI
 2
−
φ
R2v
∂R
∂v
u2 vð Þ: ð64Þ
S-factor
Uncertainties associated with S-factors are somewhat less com-
plicated than in the case of cumulated activity, and are predom-
inantly influenced by the uncertainty associated with the vol-
ume. The general approach to determining S-factors is to choose
a value calculated for a model that closely approximates the
organ or region of interest. If a model of the corresponding size
does not exist, a scaling can be applied to adjust the S-factor
accordingly. Alternatively, an empirical S-factor versus mass
representation can be obtained by fitting suitable S-factor data
against mass [21, 22]. The implicit assumption is that appropri-
ate models exist for the clinical situation. There are uncertainties
associated with deviations between the model and reality (for
example, a tumour that is not spherical) but these are outside the
scope of this framework. Figure 6 shows, on a log-log scale, an
example of S-factor data for unit density spheres of different
masses [23], empirically fitted by the function:
S ¼ c1m−c2 : ð65Þ
It is possible to apply the same principles as employed in
the previous section to determine a covariance matrix for the
estimated parameters in the fitting function. However, in this
instance the standard uncertainties associated with these fit
parameters tend to be very small (<1%) and the mass uncer-
tainty dominates. Therefore, these estimated parameter uncer-
tainties can be ignored and, using Eq. 31, the standard uncer-
tainty in S is:
u Sð Þ ¼ ∂S
∂m
 u mð Þ ¼ −c1c2m−c2−1 u mð Þ ¼ c2j j Sm u mð Þ: ð66Þ
Given that mass is proportional to volume, and assuming a
known tissue density with negligible uncertainty, the fraction-
al standard uncertainty associated with S is:
u Sð Þ
S
¼ c2j j u vð Þv : ð67Þ
The fractional standard uncertainty associated with S is
thus proportional to the fractional standard uncertainty asso-
ciated with volume v, the proportionality constant being the
magnitude |c2| of the slope of the fitting function on a log-log
scale.
Absorbed dose
Having established standard uncertainty expressions for ~A and
S, it is evident that both parameters have a dependence on
volume. To determine a final uncertainty in the absorbed dose,
the covariance between these parameters should therefore be
determined. Applying the GUM, [15] (formula F.2) the co-
variance u ~A; S
 
is evaluated using:
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Fig. 6 Example plot of S-factor versus mass for the radionuclides
indicated for unit density spheres
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u ~A; S
 	
¼ ∂
~A
∂v
∂S
∂v
u2 vð Þ: ð68Þ
An expression for ~A with respect to volume is difficult to
derive. However, using LPU [15] (formula 12) and with only
the systematic uncertainty component in ~A having a volume
dependence,
us ~A
 	
¼ ∂
~A
∂v
u vð Þ: ð69Þ
Using Eq. 51, the fractional standard uncertainty in ~A can
be replaced with that of activity to give:
∂Ai
∂v
u vð Þ
Ai
¼ ∂
~A
∂v
u vð Þ
~A
: ð70Þ
Hence,
u ~A; S
 	
¼ ∂Ai
∂v
∂S
∂v
u2 vð Þ
~A
Ai
: ð71Þ
∂S
∂v is obtained from Eq. 65: with v in place of m,
∂S
∂v
¼ −c2
v
S: ð72Þ
To provide ∂Ai∂v requires a re-expression of activity as a
function of volume. Use of Eq. 37 and differentiating with
respect to v yields:
∂Ai
∂v
¼ 1
QR
∂Ci
∂v
−
Ci
QR2
∂R
∂v
: ð73Þ
Using Eq. 26 gives:
∂Ai
∂v
¼ Ai
R
φ
2v
−
∂R
∂v
 
ð74Þ
such that covariance between ~A andS can be expressed as:
u ~A; S
 	
¼ − c2
Rv
~AS
φ
2v
−
∂R
∂v
 
u2 vð Þ: ð75Þ
Having established expressions for covariance uncertainty
in ~A and S, Eqs. 75, 67 and 64 can be used in Eq. 8 to give a
final uncertainty in absorbed dose, given by:
u2 D
 	
¼ g⊤eA;Sh iV ~A;Sh ig ~A;Sh i; ð76Þ
where g ~A;S½  and V ~A;S½  are the respective gradient and covari-
ance matrices associated with ~A and S which, using Eq. 13 for
the case of a single exponential TAC, can be written:
u D
 	
D
24 352 ¼ u A0ð Þ
A0
 2
þ u
2 λð Þ
λ
 2
−2
u A0;λð Þ
A0λ
þ u Qð Þ
Q
 2
þ u Rð Þ
R
 2
þ u Cið Þ
Ci
 2
−
φ
R2v
∂R
∂v
u2 vð Þ
þ c2j j2 u vð Þv
 2
−2
c2
Rv
φ
2v
−
∂R
∂v
 
u2 vð Þ:
ð77Þ
Patient example
An example to demonstrate the implementation of the approach
described in this paper is given in the following sections, with
details of the methodology used to obtain the absorbed dose
data and the associated uncertainty analysis. The example given
is that of a 47-year-old patient who presented with weight loss,
lethargy and upper abdominal cramps. Upper gastrointestinal
endoscopy showed a mass in the third part of the duodenum. A
subsequent contrast-enhanced CT scan and 68Ga-DOTATATE
PET/CT investigation showed a 6.5-cm mass arising from the
pancreatic head and a 3-cm mass within segment 4 of the liver,
in keeping with a neuroendocrine tumour arising from the pan-
creas. The patient underwent 90Y-DOTATATE radiopeptide
therapy in combination with 111In-DOTATATE for imaging.
The administered activity was 4,318 MBq of 90Y with 111In
given at a ratio of 1:25.
Image acquisition
Absorbed doses for the lesions were calculated using sequen-
tial 111In SPECT acquisitions, performed at 19.7 h, 45.1 h and
66.5 h after administration, acquiring 64 projections in a 128
matrix for 60 s per view. Triple-energy window scatter correc-
tions were applied to the projection data with 20% energy
windows centred on the 171 keV and 245 keV photopeaks.
The scatter-corrected data for each energy window were then
added and reconstructed iteratively with a weighted attenua-
tion coefficient based on the photopeak abundance as de-
scribed by Seo et al. [24]. The reconstructed SPECT voxel
size was 4.67 mm. 111In-DOTATATE SPECT images are
shown in Fig. 7 alongside the 68Ga-DOTATATE PET/CT im-
ages. The primary tumour and the hepatic lesion are indicated
on the images from the two modalities.
Volume
VOIs of the two lesions were determined using an adaptive
thresholding technique, whereby a threshold for outlining was
chosen based on the known threshold required to outline sim-
ilar sized volumes on phantom data. As the VOI was drawn
directly on the SPECT data, the voxelization uncertainty was
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combined with the spatial resolution element, given in Eq. 19.
The reconstructed system spatial resolution was determined
directly from physical measurements of a point source in air.
The measured FWHM was 0.9 cm. Volumes and uncertainty
components are shown in Table 1.
Recovery coefficient
Recovery data were generated by imaging multiple phan-
toms with the same acquisition and processing parameters
as described for the patient data. The phantoms consisted
of a 20 cm × 12 cm cylindrical phantom within which
smaller inserts could be placed. Insert volumes ranged
from 0.1 ml to 200 ml and were filled with a known con-
centration of 111In. For each insert two VOIs were drawn.
The first set of VOIs were generated by selecting the ap-
propriate percentage threshold to match the known physi-
cal volume of the insert. The second set of VOIs were
drawn to encompass all counts (including spill out) that
originated from the insert volume. A recovery coefficient
for each insert was then determined using Eq. 32. The
generated recovery curve is given in Fig. 8. The empirical
function fitted to the example data takes the form of a two-
parameter logistic function, with respect to volume v [25],
namely:
R vð Þ ¼ 1− 1
1þ vb1
 	b2 : ð78Þ
Fit parameters of the curve with associated uncertainties
were determined using GraphPad Prism fitting software (La
Jolla, CA, USA) and are detailed in Table 2. The covariance
between the parameters was calculated as 0.0155, which can
be expressed as a correlation coefficient, r, defined as:
r b1; b2ð Þ ¼ u b1; b2ð Þu b1ð Þu b2ð Þ ¼ 0:213 ð79Þ
Equations 33 and 34 were used to combine the volume
uncertainties with the recovery coefficient uncertainty for both
lesions as shown in Table 3. Uncertainty estimates are given
with and without the volume component. The importance of
propagating the volume uncertainty into the calculation is
clearly apparent for the smaller of the two lesions.
Count rate
Count rates for each lesion with each scan time are shown
in Table 4 with the associated fractional standard uncer-
tainties. The uncertainty in the VOI count rate is described
in Eq. 31.
Fig. 7 111In-DOTATATE SPECTand 68Ga-DOTATATE PET/CT images
of neuroendocrine tumours in a patient treated with 90Y-DOTATATE
radiopeptide therapy. Arrows indicate the lesions for which doses are to
be calculated
Table 1 Volumes and associated standard uncertainties for liver and
pancreatic lesions
Volume (cm3) Fractional standard uncertainty (%)
Due to
voxelization
Due to
resolution
Combined
Liver lesion 13.9 19.1 54.4 57.6
Pancreatic lesion 142.0 8.8 25.1 26.6
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Fig. 8 A recovery curve used to correct for partial volume losses for
objects of different sizes. The solid line indicates the fitted function and
the dotted lines indicate the lower and upper limits of the 95% confidence
interval of the fitted function
Table 2 Recovery curve fit parameters and associated standard
uncertainties
Parameter Value Standard
uncertainty
Fractional standard
uncertainty (%)
b1 21.1 ml 1.2 ml 5.8
b2 1.06 0.06 5.6
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The covariance between the recovery coefficient and
count rates, u(R,C), is defined in Eq. 48, which when com-
bined with the empirical function given in Eq. 78 can be re-
expressed as:
u CI ;Rð Þ ¼
φCIb2 vb1
 	b2
2Rv2 1þ vb1
 	b2 2 u2 vð Þ: ð80Þ
Substitution of the fit parameters, volumes and count rates
into this expression is used to generate the values for covari-
ance which are shown in Table 5. Correlation coefficients
relating to these covariance values are 0.99 and 0.92 for the
liver and pancreatic lesion, respectively.
Calibration
The systemwas calibrated by imaging point sources of 111In at
various activities (8 MBq to 30 MBq) in air using the same
acquisition parameters as for the patient scans. Images were
reconstructed according to the clinical protocol and a spherical
VOI was placed over the reconstructed point, ensuring that all
counts from the source were contained. A plot of VOI count
rate versus activity is given in Fig. 9.
The fractional standard uncertainty in activity was tak-
en as 1.5%, the typical uncertainty for secondary standard
calibrators for 111In as given by Gadd et al. [20]. The
statistical uncertainty from repeating the calibration mea-
surement was taken from the standard deviation of the
mean. Combining these uncertainties, as shown in
Eq. 36, yields:
Q ¼ 275 cps=MBq;with a standard error of 8 cps=MBq:
Activity
Calculation of 111In activity within each lesion is obtained
from Eq. 37 using the measured count rate Ci, volume-
specific recovery coefficient R and calibration factor Q. 111In
activity was converted to 90Y activity by scaling the ratio of
the administered activities and correcting for decay according
to the different half-lives of the two isotopes, such that the 90Y
activity is expressed as:
A 90Y
 
t ¼ A 90Y
 
adminA

111In
	
t
A 111In
 
admin  e λ111In−λ90Yð Þt
ð81Þ
The variance associated with the measured activity is given
in Eq. 50 and assumes negligible uncertainty in the adminis-
tered isotope activities. It is therefore a simple case of
substituting the relevant variance and covariance values for
Q, R and C to form the required uncertainty in Ai. These
activities and associated uncertainties are shown in Table 6.
TAC fitting
The Gauss-Newton algorithm was used to minimize the ob-
jective function described by Eq. 52. A single exponential
function was fitted to the data and the uncertainties in the fit
parameters A0 and λ were determined using Eq. 53. TACs for
the two lesions are given in Fig. 10 with the fitted exponential
Table 3 Recovery coefficients and associated standard uncertainties
with and without the volume component for liver and pancreatic lesions
R u(R)[b]/R u(R)[b,v]/R
Liver lesion 0.39 4.3% 37.4%
Pancreatic lesion 0.88 1.4% 3.6%
Table 4 Count rates and associated standard uncertainties for liver and
pancreatic lesions
VOI Count rate (cps) Fractional standard
uncertainty (%)
Scan 1 Scan 2 Scan 3
Liver lesion 56.8 23.2 18.0 58.6
Pancreatic lesion 865 480 292 13.6
Table 5 Covariance values of count rate and recovery coefficient at
each scan for the liver and pancreatic lesions
Scan u(R,C)
Liver lesion Pancreatic lesion
1 4.84 3.42
2 1.98 1.90
3 1.54 1.16
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Fig. 9 Activity versus count rate of reconstructed point sources in air
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functions. Error bars on the data points represent the estimated
standard uncertainty in activity.
Solution parameters with associated random and systemat-
ic components of uncertainty for each TAC are shown in
Table 7.
Cumulated activity
The covariance matrix for the solution parameters Vp is
given in Table 8. The product of the covariance matrix and
the gradient matrix gp was used to determine the random
component of the variance of ~A described in Eq. 58.
Random and systematic components of uncertainty in the
cumulated activity were determined according to Eqs. 50 and
60. These results and that of combined uncertainty (Eq. 63)
are shown in Table 9.
S-factors
The S-factors for the lesions were determined by fitting 90Y S-
factor data for unit density spheres against mass [21],
empirically fitted by the function:
S ¼ c1m−c2 : ð82Þ
The fit parameters of the curve with associated uncertainty
were determined using GraphPad fitting software (La Jolla,
CA, USA) and are shown in Table 10. As the standard uncer-
tainties associated with these fit parameters are much less than
the mass uncertainty of the two lesions the estimated param-
eter uncertainties can be ignored and Eq. 66 holds. Table 11
shows the determined S-factors for the lesions with associated
uncertainties.
Absorbed dose
The uncertainty in the absorbed dose is determined from
Eq. 13, for which the covariance u ~A; S
 
is required. Use of
Eq. 75 to determine this covariance requires solving the partial
derivative ∂R∂v and substituting the determined parameters S; ~A;
R; v; c1; c2 and the standard uncertainty u(v). For the recovery
function defined in Eq. 78, the partial derivative is expressed
as:
∂R
∂v
¼
b2 vb1
 	b2
v 1þ vb1
 	b2 2 ð83Þ
Solutions for u ~A; S
 
are shown in Table 12. It can be seen
from the correlation coefficients that the covariance between ~A
and S is highly significant. In addition, the negative nature of
Table 6 90Yactivities and associated fractional standard uncertainty for
liver and pancreatic lesions
VOI 90Y activity (MBq) Fractional standard
uncertainty (%)
Scan 1 Scan 2 Scan 3
Liver lesion 13.1 5.3 4.0 22.1
Pancreatic lesion 88.3 48.2 29.0 10.9
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Fig. 10 TAC for liver (a) and pancreatic (b) lesions. Error bars for each point are the standard uncertainty of the measured activity.Dotted lines indicate
the 95% confidence intervals due to systematic uncertainty in activity combined with the parameter uncertainties in the fitting algorithm
Table 7 TAC parameters and associated standard uncertainties for liver and pancreatic lesions
Liver lesion Pancreatic lesion
Fitted value Standard uncertainty Fractional uncertainty (%) Fitted value Standard uncertainty Fractional uncertainty (%)
A0 (fitting) (MBq) 19.6 5.10 26.1 141.2 0.2 0.1
λ (fitting) (h−1) 0.026 0.008 32.4 0.0238 3.0 × 10−5 0.1
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the correlation results in a reduction in the final absorbed dose
uncertainty, as shown in Table 13.
Propagation of uncertainty can be visualized by examina-
tion of the fractional uncertainty of each parameter calculated
along the dosimetry chain. Figure 11 gives uncertainties for
the absorbed doses delivered to lesions and to normal organs.
It can be seen that the small volume of the liver lesion has a
significant impact on the larger fractional uncertainty com-
pared to the larger lesion and organ volumes.
Using the methodology described, absorbed doses to
lesions and normal organs were calculated. In addition,
the treatment was repeated for four cycles and an equiv-
alent methodology was employed. Dosimetry results for
lesions and normal organs delivered at each fraction are
presented in Table 14 and shown graphically in Fig. 12. A
significant decrease in absorbed dose to the lesions was
observed after the first cycle and an increase in absorbed
dose to the kidneys after the fourth cycle.
Propagation of uncertainties from a tracer
to a therapy study
A further potential source of uncertainty is the use of a
pretherapy or concomitant diagnostic tracer study to predict
the absorbed dose that would be delivered from a different
therapeutic agent. It has previously been shown that uncertain-
ty in the estimation of the biological half-life of the tracer will
have an impact on the uncertainty of the absorbed dose calcu-
lated for the therapy procedure as a function of the relative
values of the biological and physical half-lives [6]. The uncer-
tainty in the therapeutic effective half-life can then be
expressed as;
u T eff thð Þ
  ¼ u T eff trð Þ T eff thð ÞT eff trð Þ
where Teff (th) and Teff (tr) are the effective half-lives of the
therapeutic and the diagnostic radionuclide, respectively.
In the limiting case of infinite biological retention, the ratio
of the uncertainties for the tracer and therapeutic agent will be
the ratio of the physical half-lives. An uncertainty in the
absorbed dose calculated for 111In (physical half-life Tphys =
67.3 h) will therefore produce a similar uncertainty in the
absorbed dose for a 90Y calculation (Tphys = 64.1 h).
However, a small uncertainty in, for example, an absorbed
dose calculation for 68Ga (Tphys = 1.13 h) would propagate
by a factor of ~60 to give potentially significant uncertainty
in a 90Y calculation.
Table 8 Covariance and gradient matrices used to calculate random (fitting) component of uncertainty in cumulated activity for liver and pancreatic
lesions
Covariance matrix Vp Gradient matrix gp Fractional standard
uncertainty in ~A (%)
Liver lesion 26:1 3:77 10−2

3:77 10−26:91 10−5 39:00½ −29722 15.1
Pancreatic lesion 0:0240 4:66 10−6

4:66 10−61:15 10−9 42:0½ −2:49 105 0.1
Table 9 Cumulated activity and associated components of standard uncertainties for liver and pancreatic lesions
Liver lesion Pancreatic lesion
Value
(MBq h)
u ~A
 
(MBq h)
Fractional
uncertainty (%)
Value
(MBq h)
u ~A
 
(MBq h)
Fractional
uncertainty (%)
~A (fitting) 115 15.1 4.0 0.0678
~A (systematic) 762 168 22.1 5,933 644 10.9
~A (total) 204 26.7 644 10.9
Table 10 Fit parameters and associated standard uncertainties for S-
factor data of unit density spheres
Parameter Fitted
value
Standard
uncertainty
Fractional
uncertainty (%)
c1 0.429 3.7 × 10
−3 0.4
c2 −0.961 5.1 × 10−3 1.2
Table 11 Summary of VOI S-factor data with standard uncertainties
u(S)
S-factor
(Gy/MBq h)
Standard
uncertainty
Fractional
uncertainty (%)
Liver lesion 3.4 × 10−2 1.9 × 10−2 55.5
Pancreatic lesion 3.7 × 10−3 0.9 × 10−3 25.5
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It is important to note that nonconformance, for ex-
ample different administered amounts or affinities be-
tween diagnostic and therapeutic radiopharmaceuticals,
will also introduce additional uncertainties into the pre-
diction [26, 27]. For example, it is assumed that the
biokinetics of 111In- and 90Y-DOTATATE are equal,
whereas the renal uptake of the indium-labelled com-
pound might be higher [28].
Discussion
The methodology presented allows uncertainty analysis to be
incorporated into absorbed dose calculations using the MIRD
schema [1], the most widely adopted approach for molecular
radiotherapy (MRT) dosimetry. The methodology is based on
the recommendations described within the GUM [14] and
necessarily involves the formation of covariance matrices for
several steps of the dosimetry process.
The main objective of this uncertainty propagation
schema is to evaluate the standard uncertainty in absorbed
dose to a target. The tasks that directly support that ob-
jective are the determination of cumulated activity and the
S-factor. The cumulated activity, given by the area under a
TAC, is obtained from a sequence of quantitative images.
Each activity value is expressed in terms of an observed
count rate, a calibration factor and a recovery coefficient.
The recovery coefficient is based on a recovery curve
derived from multiple phantom scans. The presence of a
common calibration and recovery factor in all activity
values, and the covariance between volume, recovery
and measured count rate, can be considered as a system-
atic uncertainty applied across all TAC data points, and
therefore may be applied directly to cumulated activity.
For the effects of uncertainties associated with random
components of TAC data, a statistical approach using a
“goodness of fit” measure is used.
Within the described schema particular functions are used
to fit the acquired data, for example for the TAC, recovery and
S-factor models. The choice of these functions is not
discussed, and an obvious fit function from theory may not
always be known. In this case an optimal function can be
found, and uncertainties reduced by using model selection
criteria and model averaging [10, 29, 30].
It is suggested that the major factors affecting uncertainty
in the absorbed dose originate from the uncertainty in the
delineation of the VOI. Two approaches to determine this
uncertainty using statistical and analytical methods are pre-
sented. In this example an assumption is made that only a
single VOI is applied to all datasets. An alternative approach
involves the individual delineation of VOIs for each time
point, for which the described methods may need to be varied,
taking care to account for any commonalities applied across
time points.
Propagation of these uncertainties to derive those fur-
ther along the dosimetry chain requires the covariance
between parameters to be evaluated. An understanding
of the variation in VOI counts with VOI uncertainty is
challenging as there is no prior knowledge of the count
distribution. A method for estimating the count distribu-
tion is therefore proposed. However, this approach does
not model noise or background counts spilling into the
VOI. A more rigorous approach would be to determine a
function for change in counts versus volume for the
dataset being analysed. However, it is considered that
Table 12 VOI S-factor data with standard uncertainties u(S)
~A u ~A
 
S (Gy/
MBq h)
u(S) (Gy/
MBq h)
u ~A;S
 
r ~A; S
 
Liver
lesion
762 203 3.4 × 10−2 1.9 × 10−2 −3.09 −0.80
Pancreatic
lesion
5,932 1,046 3.7 × 10−3 0.9 × 10−3 −0.57 −0.95
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Fig. 11 Fractional uncertainty of calculated dosimetric parameters for
lesions and normal organs
Table 13 Absorbed dose parameters and associated standard uncertainties for liver and pancreatic lesions
Absorbed dose (Gy) Covariance matrix, V ~A;S½  Gradient matrix, g ~A;S½  Fraction uncertainty in D (%)
Liver lesion 26.1 4:16 104 −3:09

−3:093:60 10−4 0:0342½ 762 37.6
Pancreatic lesion 21.7 4:15 105 −0:572

−0:5728:71 10−7 0:00365½ 5932 15.6
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the approach suggested is sufficient since it does not over-
ly complicate the methodology or require additional im-
age processing or analysis, which is not available to the
wider nuclear medicine community.
An important feature of the schema is that it can be easily
implemented using standard nuclear medicine image process-
ing techniques. This feature is demonstrated in the clinical
example in which absorbed dose calculations were performed
using a standard image processing workstation and a commer-
cial spreadsheet with curve-fitting software. Clinical imple-
mentation of this approach clearly demonstrates how different
aspects of the dosimetry calculation can influence uncertainty.
Uncertainty pertaining to a smaller lesion is clearly affected by
the ability to define precisely the lesion volume and can be
significant. For larger organs (such as the liver) volume delin-
eation is less significant and the fit to the TAC begins to
dominate. The ability to determine the source of larger uncer-
tainties facilitates optimization of dosimetry protocols.
The clinical example given in the appendix demon-
strates the importance of uncertainty in reviewing the
significance of results. Figure 12 shows the variation in
absorbed doses measured in different treatment cycles.
With the presence of uncertainties indicated by error
bars, it is possible to determine where a significant dif-
ference in delivered absorbed dose occurs. If absorbed
dose measurements are to be used to aid future treatment
(the goal of MRT dosimetry) it is possible that different
treatment strategies could be adopted if the absorbed
doses delivered are seen to be constant or decrease with
sequential cycles. The uncertainty given in the example
demonstrates the utility of the guidance to help identify
aspects of the calculations that can be addressed to im-
prove accuracy. It is important to note that the scale of
uncertainties should be considered in relation to the
range of absorbed doses that are delivered from standard
administrations.
Whilst the clinical example demonstrates the use of the
schema for SPECT-based dosimetry, the methodology can
easily be adapted to suit alternative dosimetry protocols (that
is, for multiexponential TAC models, external probe counting
or 3D dosimetry). However, variations to the proposed sche-
ma should always follow the uncertainty guidelines set out by
the GUM.
Uncertainty analysis is important for any measured or calcu-
lated parameter, whether physical or biological. Such calcula-
tions for MRT are rare [5] and leave room for systematic im-
provement.With the rapid expansion ofMRTand an increase in
the number of centres performing dosimetry, it is important for
adequate interpretation of the data in clinical practice that mea-
surement uncertainties are quoted alongside absorbed dose
values. The application of uncertainty analysis may increase
the validity of dosimetry results and may become the basis for
quality assurance and quality control. Uncertainty analysis may
help identify and reduce errors, aiming at an increased likeli-
hood of observing actual dose–response relationships, which in
turn would lead to improved treatment regimens.
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Fig. 12 Absorbed doses to lesions and normal organs over four treatment
cycles. Error bars represent standard uncertainties in the dose values
Table 14 Absorbed doses with standard uncertainties for lesions and normal organs over treatment cycles
Cycle 1 Cycle 2 Cycle 3 Cycle 4
D (Gy) u D
 
(Gy) D (Gy) u D
 
(Gy) D (Gy) u D
 
(Gy) D (Gy) u D
 
(Gy)
Liver lesion 26.1 9.8 17.8 6.2 13.4 4.6 11.5 4.1
Pancreatic lesion 21.7 3.4 14.3 2.2 10.8 2.2 9.9 1.8
Kidneys 6.68 0.3 6.9 0.8 6.1 0.7 8.0 0.8
Spleen 15.4 1.9 15.4 2.5 12.3 2.2 13.0 2.6
Liver 2.54 0.6 2.4 0.2 2.1 0.1 2.0 0.2
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